Compare Fox Corp Class A (FOXA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Sanofi SA — how do they compare? Fox Corp Class A trades at $63.66 (market cap $25.36B), while Sanofi SA trades at $40.21 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 3.8× Fox Corp Class A's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Sanofi SA for 94 Days on average.
| FOXA | SNY | |
|---|---|---|
Market Cap | $25.36B | $95.18B |
Volume | 2,566,954 | 2,995,646 |
Sector | Media | Health |
52-Week High | $76.11 | $52.34 |
52-Week Low | $48.79 | $39.51 |
Typical Hold Time | 34 Days | 94 Days |
Enterprise Value | $28.72B | $114.48B |
Dividend Yield | 0.91% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $63.42, up 1.15% with a bullish technical signal and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats and solid profitability metrics including 14.29% ROE and 9.84% net margin. Recent news highlights the pending Roku acquisition and regulatory scrutiny, while institutional activity shows CEO Lachlan Murdoch's significant $10.3 million share purchase in September 2026.
The outlook remains positive with a $72 consensus price target representing 13.5% upside potential. Key opportunities include continued earnings growth and strategic acquisitions, while risks center on regulatory approval for the Roku deal and potential market volatility. With no analyst sell ratings and strong institutional support, FOXA presents a compelling investment case in the media sector.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
